Teva begins cuts at NY plant it expects to shutter by early next year

teva

Israel-based Teva Pharmaceuticals ($TEVA) has begun letting staff go at its Pomona site in Haverstraw, NY, that the company expects to close by February. That facility produces niacin, which is used to treat cholesterol and triglyceride levels.

The company notified about 80 of the 236 people working at the plant earlier this week.

“Closure of the Pomona site has been under consideration for a period of time,” company spokeswoman Michele Pelkowski, a company spokeswoman told The Journal News of the Lower Hudson Valley. “And Teva’s Pomona-based employees were informed previously of this possibility.”

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Teva acquired the plant, which also has some R&D operations at the site, in 2008 when it purchased Barr Pharmaceuticals. The company has previously said it planned to consolidate its R&D operations in Elizabeth, NJ. Teva also has New York operations in Fairfield, Buffalo, and Coplague.

R&D workers in Haverstraw are expected to be offered a chance to interview for jobs in New Jersey.

Teva completed its nearly $40 billion deal for generic drug maker Allergan ($AGN) in early August. The company has since said it wants throw an additional $500 million into the acquisition to buy Allergan’s supply chain operation Anda, the fourth largest drug distributor in the U.S.

- check out The Journal News story

Read more:
Teva wants Allergan's distribution biz now that $40B drug deal has closed 
With Allergan deal sealed, Teva turns its attention to branded M&A 
McKesson extends its Canada supply chain reach with $2.23B deal for Rexall chain 
Drug distributor McKesson laying off 1,600 
AmerisourceBergen lays out $2.5B for sterile compounder PharMEDium

Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.